CHERISH: Motor function results

SPINRAZA® patients demonstrate significant and sustained improvement in motor function1

  • At the final analysis, patients treated with SPINRAZA® experienced a 3.9-point increase in HFMSE versus a 1.0-point decline in sham-control patients (p=0.0000001)1

Change in total HFMSE score (primary endpoint)*1


*Shown is the least-squares mean change from baseline to the time of each trial assessment in the Hammersmith Functional Motor Scale–Expanded (HFMSE) score in the final analysis. HFMSE scores range from 0 to 66, with higher scores indicating better motor function; a change in the HFMSE score of at least 3 points is considered to be clinically meaningful. Error bars indicate standard errors.1


age 6 years*
Later-onset (Type II) SMA
treated with SPINRAZA®
~4 years as of 9/18

*Age at time of photo shoot.

1. SPINRAZA® Summary of Product Characteristics.